Market revenue in 2021 | USD 17.7 million |
Market revenue in 2030 | USD 135.2 million |
Growth rate | 25.3% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 32.77% in 2021. Horizon Databook has segmented the Australia non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
Rapid diagnostic techniques are essential for early diagnosis of NASH and in deciding appropriate treatment options. Growing prevalence of diabetes and obesity is increasing the economic burden on the Australian government, resulting in an increase in research activities pertaining to the detection of novel drug development biomarkers for NASH.
Even if Australia's obesity prevalence stabilizes, NAFLD-related morbidity and mortality are expected to increase. Between 2019 and 2030, there will be an estimated 1.4 million increase in the number of Australians aged 65 and above.
The population will be more at risk for advanced liver disease as the average age rises. The projection for prevalent NASH cases increased by 40% from 1,317,000 to 1,848,000 cases between 2019 and 2030. This supports market growth in the near future.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Australia non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account